| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 23 | 2023 | 131 | 4.900 |
Why?
|
| Neoplasms | 17 | 2023 | 147 | 3.880 |
Why?
|
| Colorectal Neoplasms | 18 | 2022 | 47 | 3.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2023 | 33 | 2.520 |
Why?
|
| Humans | 85 | 2024 | 14537 | 1.440 |
Why?
|
| Camptothecin | 7 | 2017 | 8 | 1.320 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2017 | 34 | 1.300 |
Why?
|
| Female | 61 | 2024 | 9103 | 1.260 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 5 | 2017 | 5 | 1.250 |
Why?
|
| Middle Aged | 44 | 2024 | 3601 | 1.220 |
Why?
|
| Delivery of Health Care | 5 | 2024 | 239 | 1.130 |
Why?
|
| South Africa | 46 | 2024 | 7596 | 1.090 |
Why?
|
| Aged | 32 | 2024 | 1740 | 1.070 |
Why?
|
| HIV Infections | 14 | 2024 | 5097 | 1.010 |
Why?
|
| Quality Improvement | 3 | 2024 | 34 | 1.000 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 62 | 0.950 |
Why?
|
| Fluorouracil | 12 | 2023 | 19 | 0.940 |
Why?
|
| Receptor, ErbB-2 | 5 | 2023 | 17 | 0.910 |
Why?
|
| Organoplatinum Compounds | 6 | 2021 | 6 | 0.890 |
Why?
|
| Comorbidity | 4 | 2020 | 188 | 0.870 |
Why?
|
| Registries | 3 | 2015 | 91 | 0.850 |
Why?
|
| Receptors, Progesterone | 4 | 2023 | 14 | 0.850 |
Why?
|
| Leucovorin | 10 | 2021 | 11 | 0.850 |
Why?
|
| Terminally Ill | 4 | 2019 | 21 | 0.840 |
Why?
|
| Receptors, Estrogen | 4 | 2021 | 14 | 0.810 |
Why?
|
| Male | 38 | 2024 | 6754 | 0.790 |
Why?
|
| Disease-Free Survival | 11 | 2021 | 25 | 0.760 |
Why?
|
| Developing Countries | 4 | 2024 | 400 | 0.750 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 468 | 0.720 |
Why?
|
| Private Sector | 2 | 2022 | 45 | 0.720 |
Why?
|
| Adult | 33 | 2024 | 5913 | 0.680 |
Why?
|
| Death | 2 | 2019 | 14 | 0.680 |
Why?
|
| Public Sector | 1 | 2020 | 82 | 0.650 |
Why?
|
| Health Care Costs | 1 | 2020 | 115 | 0.640 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 10 | 0.630 |
Why?
|
| Terminal Care | 4 | 2020 | 35 | 0.620 |
Why?
|
| Proportional Hazards Models | 7 | 2022 | 163 | 0.620 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2017 | 3 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 7 | 2016 | 142 | 0.610 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 43 | 0.590 |
Why?
|
| National Health Programs | 2 | 2022 | 78 | 0.570 |
Why?
|
| Neoplasm Metastasis | 10 | 2020 | 11 | 0.550 |
Why?
|
| Liver Neoplasms | 4 | 2020 | 59 | 0.510 |
Why?
|
| Cohort Studies | 8 | 2024 | 967 | 0.500 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2024 | 77 | 0.480 |
Why?
|
| Colonic Neoplasms | 2 | 2023 | 7 | 0.410 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 106 | 0.410 |
Why?
|
| Health Care Reform | 1 | 2012 | 20 | 0.400 |
Why?
|
| Neoplasm Staging | 8 | 2023 | 50 | 0.400 |
Why?
|
| Age Factors | 7 | 2019 | 370 | 0.400 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 25 | 0.390 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2020 | 51 | 0.380 |
Why?
|
| Palliative Care | 4 | 2020 | 52 | 0.370 |
Why?
|
| Cetuximab | 4 | 2020 | 4 | 0.370 |
Why?
|
| ErbB Receptors | 5 | 2020 | 14 | 0.370 |
Why?
|
| Young Adult | 9 | 2020 | 2498 | 0.360 |
Why?
|
| Prospective Studies | 8 | 2024 | 1160 | 0.350 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 1324 | 0.330 |
Why?
|
| Femur | 1 | 2009 | 11 | 0.330 |
Why?
|
| Bone Marrow Transplantation | 2 | 2008 | 3 | 0.330 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 146 | 0.330 |
Why?
|
| DNA | 1 | 2009 | 73 | 0.320 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2023 | 19 | 0.320 |
Why?
|
| Mastectomy | 2 | 2020 | 10 | 0.320 |
Why?
|
| Double-Blind Method | 6 | 2017 | 272 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 16 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 14 | 0.310 |
Why?
|
| Specimen Handling | 1 | 2009 | 105 | 0.310 |
Why?
|
| Sarcoma, Kaposi | 8 | 2008 | 53 | 0.310 |
Why?
|
| Prognosis | 6 | 2023 | 199 | 0.310 |
Why?
|
| Caregivers | 2 | 2019 | 76 | 0.290 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2020 | 115 | 0.280 |
Why?
|
| Survival Rate | 6 | 2018 | 96 | 0.270 |
Why?
|
| Hypertension | 2 | 2023 | 419 | 0.270 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 5 | 0.240 |
Why?
|
| Melanoma | 1 | 2024 | 9 | 0.240 |
Why?
|
| ras Proteins | 3 | 2014 | 3 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2014 | 7 | 0.230 |
Why?
|
| Politics | 1 | 2024 | 24 | 0.230 |
Why?
|
| Case-Control Studies | 5 | 2023 | 480 | 0.230 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2023 | 4 | 0.220 |
Why?
|
| Leukopenia | 1 | 2023 | 4 | 0.220 |
Why?
|
| Adolescent | 8 | 2020 | 2985 | 0.220 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2023 | 9 | 0.210 |
Why?
|
| Ki-67 Antigen | 2 | 2023 | 13 | 0.210 |
Why?
|
| Population Surveillance | 2 | 2015 | 325 | 0.210 |
Why?
|
| Paraproteinemias | 1 | 2022 | 2 | 0.210 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 3 | 0.210 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 12 | 0.210 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 32 | 0.210 |
Why?
|
| Noncommunicable Diseases | 1 | 2023 | 77 | 0.200 |
Why?
|
| Hospitals, Public | 2 | 2021 | 45 | 0.200 |
Why?
|
| Age Distribution | 3 | 2018 | 107 | 0.200 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2022 | 11 | 0.200 |
Why?
|
| Genes, ras | 2 | 2013 | 2 | 0.190 |
Why?
|
| Treatment Outcome | 8 | 2024 | 889 | 0.190 |
Why?
|
| Exons | 2 | 2014 | 17 | 0.190 |
Why?
|
| Breast | 2 | 2021 | 10 | 0.190 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 1 | 0.190 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 370 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 20 | 0.180 |
Why?
|
| Cisplatin | 2 | 2006 | 5 | 0.180 |
Why?
|
| Mammography | 1 | 2020 | 3 | 0.180 |
Why?
|
| Vaginal Fistula | 1 | 2020 | 1 | 0.180 |
Why?
|
| Intestinal Fistula | 1 | 2020 | 2 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 14 | 0.180 |
Why?
|
| Intestinal Perforation | 1 | 2020 | 5 | 0.180 |
Why?
|
| Sampling Studies | 1 | 2020 | 13 | 0.180 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 353 | 0.170 |
Why?
|
| Polymorphism, Genetic | 2 | 2023 | 99 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 39 | 0.170 |
Why?
|
| Obesity | 2 | 2023 | 367 | 0.170 |
Why?
|
| Drug Administration Schedule | 5 | 2024 | 156 | 0.170 |
Why?
|
| Doxorubicin | 3 | 2018 | 8 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2019 | 62 | 0.160 |
Why?
|
| Blast Crisis | 1 | 1999 | 1 | 0.160 |
Why?
|
| Nucleoside-Phosphate Kinase | 1 | 1999 | 1 | 0.160 |
Why?
|
| src Homology Domains | 1 | 1999 | 1 | 0.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 5 | 0.160 |
Why?
|
| Attitude to Death | 1 | 2019 | 6 | 0.160 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 15 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2018 | 6 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2020 | 125 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 435 | 0.160 |
Why?
|
| Viral Load | 2 | 2022 | 819 | 0.160 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 1 | 0.160 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 14 | 0.150 |
Why?
|
| Membrane Proteins | 2 | 2013 | 36 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 42 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2018 | 7 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2019 | 34 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 9 | 0.150 |
Why?
|
| Patient Preference | 1 | 2018 | 30 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 2 | 0.150 |
Why?
|
| Clofazimine | 1 | 1998 | 8 | 0.150 |
Why?
|
| Age of Onset | 1 | 2018 | 32 | 0.150 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 3 | 0.150 |
Why?
|
| Mutation | 5 | 2020 | 306 | 0.140 |
Why?
|
| Carcinoma | 1 | 2016 | 9 | 0.140 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2007 | 4 | 0.140 |
Why?
|
| Disease Progression | 2 | 2014 | 154 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2018 | 167 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2018 | 656 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2023 | 107 | 0.130 |
Why?
|
| Erythrocyte Membrane | 1 | 1996 | 2 | 0.130 |
Why?
|
| Blood Proteins | 1 | 1996 | 2 | 0.130 |
Why?
|
| Leukemia, Myeloid | 1 | 1995 | 5 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 1995 | 5 | 0.120 |
Why?
|
| World Health Organization | 1 | 2016 | 137 | 0.120 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2014 | 1 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2003 | 187 | 0.120 |
Why?
|
| HIV-1 | 4 | 2008 | 1260 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2023 | 7 | 0.120 |
Why?
|
| Ondansetron | 1 | 1994 | 1 | 0.110 |
Why?
|
| Granisetron | 1 | 1994 | 1 | 0.110 |
Why?
|
| Vomiting | 1 | 1994 | 4 | 0.110 |
Why?
|
| Bevacizumab | 3 | 2020 | 3 | 0.110 |
Why?
|
| Tamoxifen | 2 | 2023 | 9 | 0.110 |
Why?
|
| Capecitabine | 2 | 2023 | 2 | 0.100 |
Why?
|
| Molecular Sequence Data | 4 | 2008 | 263 | 0.100 |
Why?
|
| Genotype | 2 | 2023 | 442 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2020 | 149 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2021 | 30 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 2 | 2023 | 253 | 0.090 |
Why?
|
| Prevalence | 4 | 2022 | 1192 | 0.090 |
Why?
|
| Consensus | 2 | 2021 | 62 | 0.090 |
Why?
|
| Temperature | 1 | 2009 | 56 | 0.080 |
Why?
|
| Dibenzocycloheptenes | 1 | 2009 | 1 | 0.080 |
Why?
|
| Taxoids | 1 | 2009 | 1 | 0.080 |
Why?
|
| Quinolines | 1 | 2009 | 14 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 44 | 0.080 |
Why?
|
| Recurrence | 1 | 2009 | 29 | 0.080 |
Why?
|
| Amelogenin | 1 | 2008 | 3 | 0.080 |
Why?
|
| Sex Determination by Skeleton | 1 | 2008 | 3 | 0.080 |
Why?
|
| Sex Determination Analysis | 1 | 2008 | 5 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 1 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 6 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 20 | 0.080 |
Why?
|
| Lymphoma, AIDS-Related | 3 | 2003 | 16 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2008 | 12 | 0.070 |
Why?
|
| Quinazolines | 1 | 2007 | 1 | 0.070 |
Why?
|
| Amyloidosis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1422 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 198 | 0.070 |
Why?
|
| Pelvis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 685 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 2 | 0.060 |
Why?
|
| Medical Assistance | 1 | 2023 | 8 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 507 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2019 | 225 | 0.060 |
Why?
|
| Filgrastim | 1 | 2023 | 4 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2003 | 14 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 26 | 0.050 |
Why?
|
| Quality of Life | 2 | 2020 | 177 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 26 | 0.050 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2022 | 9 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 176 | 0.050 |
Why?
|
| Podophyllin | 1 | 2002 | 2 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2023 | 42 | 0.050 |
Why?
|
| Genes, MDR | 1 | 2002 | 4 | 0.050 |
Why?
|
| Estradiol | 1 | 2002 | 18 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 3 | 2007 | 4 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2022 | 16 | 0.050 |
Why?
|
| Africa | 2 | 2021 | 376 | 0.050 |
Why?
|
| Risk Factors | 2 | 2022 | 1475 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2003 | 284 | 0.050 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2021 | 8 | 0.050 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2021 | 17 | 0.050 |
Why?
|
| Research Report | 1 | 2021 | 11 | 0.050 |
Why?
|
| United States | 1 | 2021 | 132 | 0.050 |
Why?
|
| Carboplatin | 1 | 2020 | 1 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 5 | 0.040 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.040 |
Why?
|
| Child | 2 | 2015 | 2242 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 48 | 0.040 |
Why?
|
| Spirituality | 1 | 2020 | 11 | 0.040 |
Why?
|
| HIV | 1 | 2023 | 380 | 0.040 |
Why?
|
| Fatigue | 2 | 2013 | 20 | 0.040 |
Why?
|
| Pain | 1 | 2020 | 41 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 18 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 171 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 1996 | 11 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 16 | 0.040 |
Why?
|
| Guanylate Kinases | 1 | 1999 | 1 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 114 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 296 | 0.040 |
Why?
|
| Diarrhea | 2 | 2013 | 76 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 7 | 0.040 |
Why?
|
| Epirubicin | 1 | 2018 | 2 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 5 | 0.040 |
Why?
|
| Mutant Proteins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 9 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 139 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 48 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2018 | 33 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2018 | 122 | 0.040 |
Why?
|
| Home Nursing | 1 | 2018 | 8 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 280 | 0.040 |
Why?
|
| Emotions | 1 | 2018 | 18 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 157 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1997 | 1 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 411 | 0.040 |
Why?
|
| Administration, Oral | 1 | 1998 | 127 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 1997 | 31 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2016 | 3 | 0.030 |
Why?
|
| Magnesium | 1 | 2016 | 6 | 0.030 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2016 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 125 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 1996 | 4 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1996 | 3 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 1996 | 2 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1996 | 17 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 1996 | 22 | 0.030 |
Why?
|
| Philadelphia Chromosome | 1 | 1995 | 1 | 0.030 |
Why?
|
| Clone Cells | 1 | 1995 | 4 | 0.030 |
Why?
|
| Program Development | 1 | 2015 | 32 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 89 | 0.030 |
Why?
|
| Hospitalization | 1 | 2018 | 418 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 89 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 227 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 1994 | 1 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1994 | 2 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1994 | 4 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 1994 | 3 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 1994 | 4 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 1994 | 6 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 1993 | 12 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 1 | 0.030 |
Why?
|
| Neutropenia | 1 | 2013 | 9 | 0.030 |
Why?
|
| Base Sequence | 2 | 2008 | 149 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 1479 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1748 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 188 | 0.020 |
Why?
|
| HIV Seronegativity | 2 | 2003 | 52 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 2244 | 0.020 |
Why?
|
| Paleontology | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 3 | 0.020 |
Why?
|
| Forensic Genetics | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2008 | 9 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2008 | 16 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2008 | 38 | 0.020 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 4 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 260 | 0.020 |
Why?
|
| Colchicine | 1 | 2007 | 1 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2007 | 1 | 0.020 |
Why?
|
| Melphalan | 1 | 2007 | 2 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2007 | 6 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2007 | 4 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2007 | 7 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2007 | 19 | 0.020 |
Why?
|
| Prednisone | 1 | 2007 | 17 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 63 | 0.020 |
Why?
|
| Disease Management | 1 | 2007 | 74 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 25 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 563 | 0.020 |
Why?
|
| Nausea | 1 | 2004 | 2 | 0.010 |
Why?
|
| Stomatitis | 1 | 2004 | 2 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2004 | 4 | 0.010 |
Why?
|
| Shock, Septic | 1 | 2004 | 10 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 111 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 14 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 20 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 7 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 65 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 48 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 1994 | 799 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1997 | 6 | 0.010 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1997 | 3 | 0.010 |
Why?
|
| Testosterone | 1 | 1997 | 14 | 0.010 |
Why?
|
| Biomarkers | 1 | 1997 | 327 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1993 | 13 | 0.010 |
Why?
|